Best Life Sciences Platforms and Tools Companies in Guangdong Province, China
The 40 best Life Sciences Platforms and Tools companies in Guangdong Province, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MGI.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Guangdong Province
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Beike Biotech Stem cell provider | — | — | Unfunded | Shengqin Ye CEO | 700 | WordPressMySQLPHP+20 | — |
| 2 | BGI Tech Provider of genome sequencing solutions | — | — | Funding Raised | — | 1,500 | — | — |
| 3 | BioWit Offers research and development services | — | — | Deadpooled | Jun huang CEO | — | — | — |
| 4 | Dakewe Biotech Provider of scientific instruments, life science reagents | — | — | Unfunded | Qingjun Wu Co-Founder & Owner | — | — | — |
| 5 | DeepAeon Provider of AI-based platform for medical imaging and gene sequencing | — | — | Deadpooled | Ren Guoqin CEO | — | — | — |
| 6 | Digifluidic Developer of digital microfluidic based diagnostic solutions for disease detection | — | — | Unfunded | Tianlan Chen Founder & CEO | — | — | — |
| 7 | Fapon Biotech Manufacturer of raw materials for IVD industry | — | — | Funding Raised | Steven Lee Founder | 124 | — | — |
| 8 | Feipeng Bio Developer of in-vitro diagnostic reagents and kits | — | — | Funding Raised | Roc Cui Co-Founder | 525 | PHPanime.jsApache HTTP Server+6 | — |
Top 12 Life Sciences Platforms and Tools companies in Guangdong Province
#1
Public · Zhongshan, Guangdong Province · founded 2012 · 2520 employees$195Mraised▾
Developer of antibody drug conjugates for the treatment of broad spectrum diseases. The company utilizes proprietary Tetrabody technology to develop pipeline of products for cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields.
- Oct 2024Post IPO$249.9M
- Nov 2019Series D$150M
- Oct 2018Series C—
- Aug 2017Series B$45M
#2
Series B · Shenzhen, Guangdong Province · founded 2014$56.7Mraised▾
Developer of automated cell processing system. It offers the CellSep PRO system which uses gradient centrifugation for customized cell preparation. It also offers the EuLV system which is a stable cell line-based lentiviral vector production system used for cell and gene therapies.
- Feb 2024Series B$41.7M
- Jun 2022Series B$14.9M
#3
Series C · Shenzhen, Guangdong Province · founded 2012$158Mraised▾
Developer of genome sequencing technology for molecular diagnosis. The products include high-throughput gene sequencers, single-molecule gene sequencers, kits for non-invasive prenatal screening, preimplantation genetic testing, tumor, and genetic disease diagnosis. The company's technology includes sequencing optical systems, synthetic sequencing chemical systems, and sequencing chips.
- Aug 2023Series C$55.7M
- Sep 2021Series B$63.6M
- Jun 2021Series B$38.7M
#4
Series B · Shenzhen, Guangdong Province · founded 2016 · 2805 employees$1Braised▾
Provider of gene sequencing instruments, reagents, equipment, and related products. The company has multi-omics platforms which include robotic ultrasound systems, sequencers, and automation systems for life science research, agriculture, precision medicine, and healthcare. It also has sequencing reagents, enzymes, an instrument for microbial detection, analyzers, and others.
- May 2020Series B$1B
- May 2019Series A—
#5
Public · Shenzhen, Guangdong Province · founded 1999 · 7 employees$300.4Mraised▾
Provider of services in genome sequencing. The company provides services in large-scale sequencing of human, plant, and animal genome. The company's major scientific accomplishments include sequencing the genome of an Asian person, the giant panda, and the human gut microbiome. It also contributed to the Human Genome Project and the rice-genome-sequencing initiative. The company's sequencing platform includes BGIseq.
- Feb 2021Post IPO$300M
- Jan 2015Grant (prize money)$350.7K
#6
Deadpooled · Dongguan, Guangdong Province · founded 2021 · 150 employees$20.3Mraised▾
Developer of technologies for multi-omics single-cell analysis. The company has technology platforms "single-cell enrichment and detection", "single-cell sequencing", and "single-cell biosynthesis analysis" to develop Digital Microfluidic Chip (DMF) Controller and a Trace single-cell sequencer. Also, it offers Automated fluorescence scanning and cell recognition system and prenatal test kits.
- Feb 2023Series A—
- Nov 2021Series A$20.3M
#7
Deadpooled · Zhuhai, Guangdong Province · founded 2014$13.8Mraised▾
Provider of serum-free cell culture technology for research services. It offers a serum-free cell culture medium for mammalian cells such as stem cells, immune cells, tumor cells, CHO, and 293 cells for the production of recombinant proteins such as monoclonal antibodies.
- Nov 2022Series A$13.8M
#8
Series A · Shenzhen, Guangdong Province · founded 2017 · 60 employees$1.6Mraised▾
Operator of a sports platform providing live streams, video replays. The platform offers access to soccer and basketball games, including news and event schedules. It provides sports enthusiasts with a way to watch games and view highlights.
- Sep 2023Series A—
- Jun 2022Series A—
- Feb 2021Series A$1.6M
#9
Series A · Shenzhen, Guangdong Province · founded 2006$15.5Mraised▾
Provides molecular biology products. The company provides with sample preparation products and porous plastic filters, specializing in the manufacturing of laboratory consumables parts and OEM services. The product portfolio of the company includes oligo synthesis, nucleic acid purification kits, protein purification kits, premix buffers, consumables & accessories, and other products.
- Nov 2021Series A$15.5M
#10
Deadpooled · Shenzhen, Guangdong Province · founded 2003 · 50 employees$23.5Mraised▾
GoodCell is providing stem cell storage services. The company's pluripotent stem cells are used to treat blood cancers and certain immunological disorders as well as diseases such as macular degeneration, Parkinson's, and diabetes. The company has certification from the FDA and CLIA/CAP.
- Oct 2020Series B$17.9M
- Dec 2019Series A$5.6M
#11
Series B · Shenzhen, Guangdong Province · founded 2015 · 11 employees$11.6Mraised▾
Shenzhen Tianshen Medical Devices provides automated chemiluminescence immunoassay platforms. The company also offers a range of reagents for their devices. The devices use serum, plasma, whole blood, peripheral blood as their sample for diagnosis.
- Jan 2020Series B$11.6M
- Series A—
- Seed—
#12
Series A · Shenzhen, Guangdong Province · founded 2020—raised▾
Provider of DNA sequencers and high-resolution imaging techniques for spatial biology studies. The company offers a range of products that include sequencers, spatial omics scopes, kits and reagents for clinical applications and fundamental research.
- May 2025Series A—
- Dec 2023Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in China
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,131 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College436
- Chinese Academy of Sciences315
- Sichuan University311
- Central South University298
- Shanghai Jiao Tong University287
- Gene8→544
- Transcriptome5→408
- Genome10→350
- Disease2→212
- Identification (biology)3→192
- Gene2→729
- Disease2→562
- Cancer4→402
- Mechanism (biology)1→341
- Metabolomics1→205
- Disease2→281
- Mechanism (biology)1→142
- Cancer2→119
- Epigenetics2→63
- Gene1→56
Where bioinformatics is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in China
China bioinformatics patent filing is accelerating — 29 filings from 46 assignees (2018–2025), led by Mobidrop Zhejiang, BGI Shenzhen, Intel; annual filings 1→11.
- Mobidrop Zhejiang6
- BGI Shenzhen5
- Intel4
- LI Yingrui3
- Beijing INST Of Radiation Medici2
- WANG JIAN2
- XIA Yudong2
- MGI TECH2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.